HC Wainwright Issues Pessimistic Forecast for HRMY Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Stock analysts at HC Wainwright reduced their FY2026 earnings estimates for shares of Harmony Biosciences in a research note issued on Thursday, November 12th. HC Wainwright analyst P. Trucchio now expects that the company will earn $3.37 per share for the year, down from their prior estimate of $3.52. HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.65 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q4 2026 earnings at $0.73 EPS, Q2 2027 earnings at $1.02 EPS, Q3 2027 earnings at $1.21 EPS, Q4 2027 earnings at $1.46 EPS, FY2027 earnings at $4.50 EPS, FY2028 earnings at $6.06 EPS, FY2029 earnings at $5.90 EPS and FY2030 earnings at $7.30 EPS.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.81 EPS for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.28). The firm had revenue of $268.92 million for the quarter, compared to analysts’ expectations of $272.05 million. Harmony Biosciences had a return on equity of 18.55% and a net margin of 18.05%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.08 earnings per share.

Other analysts have also issued research reports about the stock. Deutsche Bank restated a “hold” rating and set a $42.00 target price on shares of Harmony Biosciences in a research report on Thursday, October 1st. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 price target on shares of Harmony Biosciences in a report on Monday, October 19th. WBB Securities raised Harmony Biosciences to a “hold” rating in a research note on Friday, October 23rd. Ladenburg Thalmann & Co. Inc. initiated coverage on Harmony Biosciences in a report on Thursday, October 15th. They set a “buy” rating and a $55.00 price objective on the stock. Finally, Wall Street Zen downgraded Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Sunday, November 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $48.00.

Harmony Biosciences Stock Performance

Shares of HRMY opened at $33.80 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.42 and a current ratio of 3.44. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of 11.33, a PEG ratio of 0.35 and a beta of 1.00. The company’s 50 day simple moving average is $38.81 and its 200 day simple moving average is $34.64. Harmony Biosciences has a 1 year low of $25.90 and a 1 year high of $43.49.

Institutional Trading of Harmony Biosciences

Several institutional investors have recently made changes to their positions in the stock. Advisors Asset Management Inc. purchased a new position in shares of Harmony Biosciences in the 3rd quarter worth $102,000. Ieq Capital LLC boosted its holdings in Harmony Biosciences by 5.7% in the third quarter. Ieq Capital LLC now owns 56,836 shares of the company’s stock valued at $2,231,000 after acquiring an additional 3,074 shares during the last quarter. Focus Advisor Solutions LLC purchased a new stake in Harmony Biosciences during the third quarter valued at about $228,000. Boston Partners grew its position in Harmony Biosciences by 1,289.9% during the third quarter. Boston Partners now owns 423,647 shares of the company’s stock valued at $16,638,000 after acquiring an additional 393,166 shares during the period. Finally, Voya Investment Management LLC grew its position in Harmony Biosciences by 24.6% during the third quarter. Voya Investment Management LLC now owns 61,604 shares of the company’s stock valued at $2,419,000 after acquiring an additional 12,143 shares during the period. 86.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Harmony Biosciences news, insider Kumar Budur sold 35,852 shares of the stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $43.05, for a total transaction of $1,543,428.60. Following the transaction, the insider owned 13,115 shares of the company’s stock, valued at $564,600.75. This trade represents a 73.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 72,406 shares of company stock worth $3,108,520 over the last ninety days. Corporate insiders own 11.00% of the company’s stock.

Recent Harmony Biosciences Headlines

Here are a few of the latest headlines about HRMY:

• Positive Sentiment: HC Wainwright raised its EPS estimates for 2028, 2029 and 2030 to $6.06, $5.90 and $7.30, respectively, and maintained a $55 price target—suggesting stronger projected earnings further out. HC Wainwright Buy rating article
• Negative Sentiment: The analyst cut EPS estimates for FY2026 to $3.37 from $3.52 and FY2027 to $4.50 from $4.69, alongside reductions to its Q4 2026 and Q2–Q4 2027 forecasts. These downward revisions point to softer expected near-term earnings.
• Negative Sentiment: Recent results also showed earnings pressure despite 12.3% year-over-year revenue growth: quarterly EPS of $0.81 fell short of the $1.09 consensus, and revenue was slightly below expectations. Harmony Biosciences profit and sales article

Harmony Biosciences Company Profile

Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for people living with rare neurological diseases. The company’s work centers on therapies intended to address significant unmet medical needs. Its lead product, WAKIX (pitolisant), is approved in the United States to treat excessive daytime sleepiness or cataplexy in adults and pediatric patients aged 6 years and older with narcolepsy. Harmony launched WAKIX in the United States in 2019. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony primarily serves the U.S. market.